Real-world use of emapalumab in hemophagocytic lymphohistiocytosis: a scoping review of published evidence

BackgroundEmapalumab, an interferon-γ (interferon-gamma)–blocking monoclonal antibody, has emerged as a targeted therapy for refractory hemophagocytic lymphohistiocytosis (HLH). This scoping review summarizes real-world evidence of its clinical use across HLH subtypes.MethodsA comprehensive search o...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Abdulrahman F. Al-Mashdali, Fatihelmgib Mohamed, Marwa Osman, Mujahid O. Abdelraof, Mona Al Rasheed, Hind Salama, Shehab F. Mohamed, Mohamed A. Yassin
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-04-01
Serie:	Frontiers in Pharmacology
Soggetti:	cytokine release syndrome emapalumab hemophagocytic lymphohistiocytosis interferon-γ blockade macrophageactivation syndrome real-world evidence
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1749084/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!